RXD:NYE-ProShares UltraShort Health Care (USD)

ETF | Trading--Inverse Equity |

Last Closing

USD 12.5422

Change

+0.00 (+0.02)%

Market Cap

N/A

Volume

5.79K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SH ProShares Short S&P500

+0.21 (+0.51%)

USD 1.38B
SOXS Direxion Daily Semiconductor B..

+0.12 (+1.10%)

USD 1.11B
PSQ ProShares Short QQQ

+0.29 (+0.82%)

USD 0.64B
SPXU ProShares UltraPro Short S&P50..

+0.28 (+1.48%)

USD 0.63B
SDOW ProShares UltraPro Short Dow30

+0.32 (+0.68%)

USD 0.23B
YANG Direxion Daily FTSE China Bear..

-0.76 (-2.27%)

USD 0.23B
RWM ProShares Short Russell2000

N/A

USD 0.20B
SPDN Direxion Daily S&P 500® Bear ..

+0.07 (+0.65%)

USD 0.17B
DOG ProShares Short Dow30

+0.07 (+0.26%)

USD 0.13B
FNGD MicroSectors FANG+ Index -3X I..

N/A

USD 0.10B

ETFs Containing RXD

RLD:CA 0.00 % 0.61 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.40% 95% A 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.40% 95% A 73% C
Trailing 12 Months  
Capital Gain 18.09% 98% N/A 84% B
Dividend Return 2.75% 62% D 52% F
Total Return 20.84% 98% N/A 85% B
Trailing 5 Years  
Capital Gain -51.44% 82% B 8% B-
Dividend Return 3.39% 72% C 7% C-
Total Return -48.05% 80% B- 7% C-
Average Annual (5 Year Horizon)  
Capital Gain 67.95% 39% F 96% N/A
Dividend Return 69.47% 39% F 96% N/A
Total Return 1.52% 58% F 35% F
Risk Return Profile  
Volatility (Standard Deviation) 432.75% 63% D 3% F
Risk Adjusted Return 16.05% 52% F 37% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.